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 2 
Abstract 1 
Multiple factors influence the survival of disseminated breast tumour cells (DTCs) in bone.  2 
Whilst gene signature studies have identified genes that predict a propensity of tumours to 3 
metastasise to bone, the bone environment is key in determining the fate of these tumour cells.  4 
Breast cancer cells locate to specific niches within the bone that support their survival, regulated 5 
by host factors within the bone microenvironment including bone cells, cells of the bone micro 6 
vasculature, immune cells and the extracellular matrix. Reproductive endocrine hormones affect 7 
bone and clinical studies across the menopausal transition have provided comprehensive 8 
understanding of the changes in the bone microenvironment during this time. Menopause is 9 
characterised by a decrease in ovarian oestradiol and inhibins, with an increase in pituitary 10 
follicle stimulating hormone and this review will focus on the role of these 3 hormones in 11 
determining the fate of DTCs in bone. Both in vivo and clinical data suggest premenopausal bone 12 
is a conducive environment for growth of breast cancer cells in bone.  Adjuvant cancer 13 
treatment aims to reduce the risk of tumour recurrence by targeting DTCs and drugs targeting 14 
the bone resorbing osteoclasts, such as bisphosphonates, have been evaluated in this setting. 15 
Both preclinical and adjuvant clinical studies and have shown that bisphosphonates ability to 16 
decrease tumour growth in bone is influenced by levels of endocrine hormones, with enhanced 17 
effects in a postmenopausal bone microenvironment.  The challenge is to understand the 18 
molecular mechanisms behind this phenomenon and to evaluate if alternative adjuvant bone 19 
targeted therapies may be effective in premenopausal women.  20 
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 3 
Introduction 21 
The process of metastatic spread from the primary breast tumour to bone is undoubtedly 22 
inefficient, with less than 0.01% of tumour cells released into the circulation able to form bone 23 
metastases (Cameron, et al. 2000).  Multiple factors influence the success or failure of these 24 
tumour cells, including their intrinsic properties and the myriad of environmental factors 25 
encountered on the journey from breast to bone.  Gene signature studies have identified genes 26 
that predict a propensity of tumours to metastasise to bone, including CAPG, GIPC1, TFF1 (Smid, 27 
et al. 2006; Westbrook, et al. 2016), but whilst these have a predictive value they cannot 28 
determine bone related disease outcomes for individual patients and are therefore not yet 29 
utilised in the clinical setting. The environment plays an important role in determining the fate 30 
of tumour cells; they have to overcome shear forces and oxidative stress in the circulation 31 
before extravasating (Massague and Obenauf 2016), once in the bone microenvironment they 32 
are vulnerable to immune surveillance.  There is evidence that breast cancer cells locate to 33 
specific niches within the bone microenvironment that will support their survival, using 34 
chemokine receptors such as CXCR4 to select for areas of ligand (CXCL12, also known as SDF-1) 35 
rich bone marrow (Muller, et al. 2001).  Tumour cells secrete various factors to modify this new 36 
environment and promote their survival, supporting dormancy and recurrence years after the 37 
primary tumour (Kang and Pantel 2013). Adjuvant therapy after removal of the primary breast 38 
tumour aims to reduce the risk of tumour recurrence by targeting single cell/small volume 39 
micrometastases that have not yet acquired the ability to sustain autonomous growth.  40 
However, it is now recognized that these small volume disseminated tumor cells (DTCs) may be 41 
in a non-proliferative state and not responsive to anti-proliferative agents (Massague and 42 
Obenauf 2016). There is therefore a need for alternative therapies that target DTCs to either 43 
initiate or maintain them in a dormant state, or that modify the microenvironment to make it 44 
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 4 
less hospitable and thereby promote tumour cell death. The bone-targeting bisphosphonates 45 
have been evaluated in large phase III adjuvant breast cancer trials and trials are ongoing with 46 
the newer agent denosumab. Both types of agents target the bone resorbing osteoclast (Oc). 47 
The bisphosphonate trials showed an interesting interplay between the prevailing endocrine 48 
environment and the efficacy of bisphosphonates; only women with postmenopausal levels of 49 
ovarian hormones (natural or chemically induced with the ovarian suppressor goserelin) showed 50 
improvements in disease outcomes with addition of bisphosphonates to standard adjuvant 51 
therapy (Coleman, et al. 2015).  This suggests that the endocrine influence on bone creates two 52 
distinct bone microenvironments (pre- vs postmenopausal) that differentially affect DTCs within 53 
them and influence therapies that target the bone resorbing Ocs.  54 
 55 
Tumour dissemination to bone and the bone microenvironment 56 
Bone metastases from breast cancer are currently incurable with a median survival of 2.3 years 57 
following diagnosis (Harries, et al. 2014).  The formation of clinically evident bone metastases 58 
represents the final part of a process of interactions between tumor cells and bone cells that 59 
may have lasted decades in patients who experience disease relapse many years after surgical 60 
excision of their primary tumour. Disseminated tumour cells (DTCs) are found in the bone 61 
marrow of a third of patients and 50% of these will develop metastatic disease during the first 62 
10 years post diagnosis (Braun, et al. 2005). Thus the presence of DTCs confers a poorer 63 
prognosis, but there is also a significant proportion of patients in whom tumour cells reach the 64 
bone marrow but do not develop into metastases, hence DTCs either die or are maintained in a 65 
state of dormancy.  When DTCs arrive in bone they interact with the host cells, including vessels, 66 
osteoblasts and osteoclasts, in a putative metastatic niche.  The bone forming osteoblasts (Ob) 67 
are derived from mesenchymal progenitor cells and lay down new unmineralised matrix in the 68 
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 5 
resorption pits formed by the bone resorbing osteoclasts (Oc).  The presence of tumour cells 69 
alters the bone microenvironment, increasing numbers/activity of Oc and decreasing 70 
numbers/activity of Ob, even prior to the development of overt bone lesions (Brown, et al. 71 
2012).  These early interactions may influence the outcome for tumour cells, determining 72 
whether they die, enter a dormant non-proliferative state or undergo early expansion to 73 
macrometastases. It is now well recognized that tumour cell fate can be influenced by multiple 74 
host factors within the bone microenvironment (see figure 1).   75 
Osteoblasts and the haematopoetic stem cells (HSCs); In normal physiology HSCs function is to 76 
contribute to haematopoesis for months or even a lifetime.  They respond to extrinsic 77 
(microenvironmental) signals to remain quiescent, to self-renew, or to undergo differentiation.  78 
The dormant state may in part be controlled by the Ob with evidence that increasing the 79 
number of Obs with parathyroid hormone (PTH) also increases the number of HSCs and the 80 
number of DTCs from subcutaneous prostate tumours (Shiozawa, et al. 2011). These DTCs are 81 
thought to be subject to the same Ob-derived signals that maintain HSC dormancy, thus 82 
maintaining tumour cell survival and contributing to relapse in bone many years after the initial 83 
diagnosis of the primary tumour. A recent study in mice has demonstrated that breast cancer 84 
cells form heterotypic adherence junctions with osteoblastic cells, resulting in activation of 85 
mTOR in the tumour cells and their proliferation to form micrometastases, implicating the 86 
osteoblasts in early progression (Wang et al, 2015). 87 
 88 
Osteoclasts; These bone resorbing cells are activated by various factors produced by tumour 89 
cells in bone, including receptor activator of nuclear factor-κB (RANK) ligand, PTH-related 90 
protein (PTHrP), interleukins 1 and 6 and macrophage inflammatory protein-1-alpha (Roodman 91 
2001).  The activation of Oc induces bone resorption and release of tumour growth factors from 92 
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the bone matrix including TGFβ, BMPs, calcium, PDGF and IGF which promote tumour growth 93 
and expansion in bone. The activity of Oc is tightly controlled under normal physiological 94 
circumstances and is coupled with the activity of Ob through coupling mechanisms like the 95 
RANKL-RANK interaction; Ob’s produce RANKL to activate Oc’s in addition to the soluble decoy 96 
receptor for RANKL, osteoprotegerin (OPG), which inhibits Oc development (Cross, et al. 2006). 97 
OPG is also secreted by numerous breast cancer cells and the expression of OPG decreases as 98 
tumour grade increases (Holen, et al. 2005).  Although the main driver of cancer-induced bone 99 
disease, the precise role of the Oc in the early stages of tumour cell dissemination to bone 100 
remains to be established. Interestingly, Ocs appear to be dispensable for hematopoietic stem 101 
cell maintenance and mobilization (Miyamoto et al., 2011), whereas Oc activity triggers growth 102 
of disseminated breast tumour cells to form overt metastases (Ottewell et al.  2014 and 2015). 103 
These data  suggest that different cell populations residing in bone marrow niches have 104 
differential interactions, potentially regulated by distinct signaling pathways.  105 
 106 
Bone microvasculature; Blood vessels within bone express adhesion proteins including P-selectin 107 
and E-selectin which are able to act as anchors for tumour cells (Nguyen, et al. 2009) and the 108 
highly fenestrated endothelial cell layer of blood vessels in bone promotes the extravasation of 109 
circulating tumour cells out of circulation and into bone (Mastro, et al. 2003). Once in bone, 110 
tumour cells are seen in close to blood vessels (see figure 2) and endothelial cells of the mature 111 
microvasculature have been shown to promote tumour cell dormancy through secretion of 112 
thrombospondin 1 (Ghajar, et al. 2013).  Dormancy is also maintained by the secretion of anti 113 
stromal derived growth factor -1 (SDF-1) micro-RNAs (miRNAs) from either endothelial cells or 114 
other stromal cells within close proximity to blood vessels. These anti-SDF1 miRNAs (miR-127, -115 
197, -222, and -223) are transferred to the tumour cells by use of gap junctions and induce 116 
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tumour cell growth arrest (Lim, et al. 2011). miRNAs have further roles in metastases and 117 
silencing of expression of miRNA-126 in breast cancer cells increased metastases to multiple 118 
sites including bone by promoting endothelial cell recruitment to breast cancer cells (Png, et al. 119 
2012).   120 
 121 
Inflammatory and immune cells; Macrophages within tumours have a dual role with some 122 
having a tumor growth suppressive action (M1) and some a growth promoting action on both 123 
tumours and blood vessels (M2).  Tumour associated macrophages (TAMs) are also able to limit 124 
the effect of anti-cancer therapies by associating with tumour blood vessels and promoting 125 
revascularization after chemotherapy in both primary breast tumours and bone metastases 126 
(Hughes, et al. 2015). In this study TAMS were attracted to these sites by the interaction of 127 
tumour expressed CXCL12 and TAM expressed CXCR4.  Within bone there is a plethora of 128 
inflammatory cells that can influence tumour cell homing and survival in bone including myeloid 129 
cells which express integrin α4β1 and facilitate tumour cell homing to bone (Papayannopoulou, 130 
et al. 2001). Both tumour cells and associated myeloid cells produce inflammatory cytokines, 131 
including interleukins 1β and 6, TNFα (Kinder, et al. 2008), which induce Ob and bone stromal 132 
cells to secrete factors which attract more myeloid cells and perpetuate the pro-tumourigenic 133 
effects by stimulating RANKL expression on Ob (Lam, et al. 2000) which activates Oc and 134 
promotes the ‘vicious cycle’ of bone metastases. In addition, PTHrP secreted from breast caner 135 
cells induces IL-6 and VEGF-A expression in Ob which enhances angiogenesis and induces 136 
expression of matrix remodeling proteases which support tumour growth in bone (Park, et al. 137 
2013).   138 
 139 
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Extracellular matrix and tumour hypoxia; Breast cancer cells that are cultured in vitro with 140 
mesenchymal stem cells (MSCs) demonstrate up regulation of lysyl oxidase (LOX),  an enzyme 141 
that catalyses cross-linking between collagens and elastins in the extracellular matix.  LOX 142 
changes the behavior of the cancer cells from an epithelial to a more invasive mesenchymal 143 
phenotype, which may promote the spread of these cells to the bone (El-Haibi, et al. 2012).  In a 144 
cohort of patients with oestrogen receptor (ER) negative (ER-) breast cancers, primary tumours 145 
that showed up regulation of genes involved in tumour hypoxia, including LOX, was associated 146 
with metastases to bone rather than lung, liver and brain (Cox, et al. 2015), suggesting that LOX 147 
may be involved in preferential homing of tumour cells  to bone.  A murine model of 148 
spontaneous ER-ve breast cancers which express LOX showed that the appearance of focal 149 
osteolytic lesions preceded the arrival of tumour cells in bone, suggesting that hypoxia-induced 150 
tumour secreted factors, including LOX, ‘primes’ the bone to receive tumour cells through an 151 
increase in Oc mediated bone resorption (Cox et al. 2015). Numerous additional extracellular 152 
matrix molecules are involved in the formation of a pre-metastatic niche, including periostin 153 
(Wang 2016), tenascin (Chiovaro 2015) and thrombospondin (Gahjar 2013) but how their 154 
levels/activity are affected by endocrine hormones remain largely unexplored. Another 155 
component of the extracellular matrix are cancer associated fibroblasts (CAF), which promote 156 
tumour growth and angiogenesis in breast cancer cells through recruitment of bone marrow 157 
derived endothelial cells through production of SDF-1 (Orimo, et al. 2005). 158 
 159 
Endocrine effects in bone 160 
The effects of endocrine hormones on bone are numerous and clinical studies across the 161 
menopausal transition have provided comprehensive understanding of the changes in the bone 162 
microenvironment during this time (Perrien, et al. 2006). As menopause is characterised by a 163 
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decrease in ovarian oestradiol and inhibins, with an increase in pituitary follicle stimulating 164 
hormone (FSH), this review will focus on the role of these 3 key hormones. The role of other 165 
hormones may also be important, with a recent study reporting a role for prolactin in the 166 
development of breast cancer bone metastasis and the associated bone disease (Sutherland et 167 
al 2016).  Prolactin has been shown to enhance bone turnover (2008), however levels decrease 168 
during menopause (Tanner et al 2011) and whether bone-targeted agents directly influence 169 
prolactin levels remain to be determined. 170 
Oestrogen has a well documented effect on osteoblasts and osteoclasts as both cell types 171 
express oestrogen receptors (ER) α and β. Oestrogen exerts its effect on bone cells by direct 172 
inhibition of osteoclastogenesis, promotes Ob-mediated bone formation, in addition to 173 
inhibiting Ob production of osteoclastic cytokines such as TGFβ (Krassas and Papadopoulou 174 
2001).  Oestrogen also maintains the number and activity of HSCs in bone (Qiu, et al. 2012), and 175 
increases the ratio of OPG/RANKL (Yan and Ye 2015).  The ability of oestrogen to affect the bone 176 
vasculature is not well described, but there is close association between osteogenesis and 177 
vasculogenesis suggesting that modification of bone will influence vessels and vice versa. 17β-178 
oestradiol can influence sub-cutaneous tumour vasculature, increasing vessel density and 179 
maintaining a more structured vasculature (Pequeux, et al. 2012). The immune system can be 180 
modified by oestrogen with evidence that oestrogen inhibits the secretion of pro-inflammatory 181 
cytokines including IL-6, TNFα and macrophage inhibitory factor from monocytes mediated 182 
through the ERα36 receptor on the surface of human peripheral monocyte (Pelekanou, et al. 183 
2016). Oestrogen also affects miRNA expression and CAFs with evidence that 17β-estradiol 184 
induces miR144 expression resulting in down-regulation of the onco-suppressor Runx1 185 
(Vivacqua, et al. 2015).  186 
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Inhibins are not abundantly expressed in bone, but radiolabelled inhibin A administered 187 
intravenously in vivo accumulates rapidly in the bone marrow (reviewed in Wilson et al)(Wilson, 188 
et al. 2012).  Its effects on bone turnover was highlighted in a cross sectional study of women 189 
aged 21-85 (n=188) where endocrine hormones were correlated to changes in serum markers of 190 
bone formation; bone specific alkaline phosphatase (BSAP), and bone resorption; 191 
carboxyterminal telopeptide of type I collagen (CTX). Inhibin A was the most accurate predictor 192 
of changes in bone formation and resorption being negatively correlated with levels of BSAP and 193 
CTX (Perrien et al. 2006), thus declining inhibins in early menopause will lead to increased bone 194 
turnover. Inhibins also influence both the adaptive and innate immune systems, affecting the 195 
development and function of immune cells (Aleman-Muench and Soldevila 2012).  The specific 196 
effects of inhibin on the immune system within bone has not been defined, however, inhibins 197 
do not have an identified downstream signaling pathway but instead bring about their effector 198 
functions by binding to the activin receptor (ACTRIIA) and inhibiting the biological actions of 199 
activin (Jeruss, et al. 2003). Activin, secreted from monocytes and bone fibroblasts, has been 200 
shown to suppress immune processes in bone (Abe, et al. 2002), suggesting the inhibin/activin 201 
pathway may be important for bone specific immune /inflammatory processes. 202 
 203 
Inhibins inhibit the secretion of follicle stimulating hormone (FSH) from the anterior pituitary.  In 204 
the previously discussed cross sectional study, FSH correlated with bone resorption markers 205 
(CTX) but not bone formation markers (BSAP) in perimenopausal women only (Perrien et al. 206 
2006). In vivo treatment of ovariectomised 14-week old mice with an antibody to β-subumit of 207 
FSH prevented OVX-induced bone loss after 4 weeks of treatment associated with increases in 208 
bone formation and inhibition of bone resorption (Zhu, et al. 2012). There is however reports 209 
suggesting that lowering FSH increases bone resorption; a prospective study of changes in bone 210 
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turnover in postmenopausal women (n=46) with inhibition of FSH, using GnRH agonists, showed 211 
a significant increase in CTX and TRAP5b (serum markers of bone resorption) with suppression 212 
of FSH, in addition to a significant increase in P1NP (a marker of bone formation)(Drake, et al. 213 
2010), thus the specific effects of FSH on bone turnover still need to be defined.  FSH has effects 214 
on HSC in bone, with evidence from in vivo models that bone derived HSC express FSH receptor 215 
and that treatment with FSH enhances haematopoetic recovery after chemotherapy (Shaikh, et 216 
al. 2016).  FSH also influences the vasculature; the FSH receptor (not normally expressed on 217 
vascular endothelium) is upregulated in the vasculature of bone metastases (Siraj, et al. 2013).  218 
The influence of FSH on bone mass has also been linked to its effects on the immune system; 219 
production of bone resorbing cytokines and BMD was evaluated in 36 healthy women (aged 20-220 
50) and showed BMD was inversely proportional to FSH levels and endogenous FSH levels 221 
correlated with circulating levels of IL-1beta, moreover, exogenous FSH induced isolated 222 
monocytes to secrete IL-1beta, TNF-alpha, and IL-6 (Cannon, et al. 2010). 223 
 224 
These data show that the endocrine hormones oestrogen, inhibin and FSH can modify multiple 225 
components resulting in very different bone microenvironments in pre- and post menopausal 226 
women.  At the time of the final menstrual period (FMP), the majority of women will have 227 
undetectable levels of inhibins (Burger, et al. 2002) however oestradiol remains detectable in 228 
serum for up to 5 years (Burger, et al. 1999).  The rise in FSH can occur up to 3-10 years before 229 
menopausal transition (Burger, et al. 2007), attributed to the decline in inhibins (Klein, et al. 230 
2004).  The differing levels of endocrine hormones in pre- and postmenopausal women will 231 
therefore exert differential effects on disseminated tumour cells (DTCs) in bone, with the 232 
potential to modify both tumour growth and response to bone targeted therapy. 233 
 234 
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Endocrine effects on tumour cells in bone 235 
In vivo the influence of endocrine hormones within the bone microenvironment in regulating 236 
the fate of DTCs has been described. 12 week old BALB/c nude mice underwent ovariectomy 237 
(OVX) and the bone microenvironment evaluated.  Within 2 weeks post procedure the bone 238 
microenvironment of OVX animals was significantly altered compared to sham animals with an 239 
increase in Oc activity and decrease in Ob activity (Ottewell, et al. 2014).  This alteration in the 240 
bone microenvironment affected breast tumour cell homing to bone following intracardiac (IC) 241 
injection of MDA-MB-231 cells 7 days post OVX, with significantly higher numbers of tumor cells 242 
in bone of control compared to OVX animals. However, at a later time point tumour growth in 243 
bone was detected in 18% of sham animals and 89% of OVX animals indicating that whilst OVX 244 
bone may be less attractive for tumour cell homing it is more conducive to survival and growth 245 
of cells that do colonise bone (Ottewell et al. 2014).  This data is supported by the results from 246 
clinical studies evaluating disease recurrence in patients following a diagnosis of breast cancer.  247 
Combined data on the incidence of bone marrow micrometastases in over 4,000 women 248 
showed that premenopausal women had significantly higher incidence of bone marrow 249 
micrometastases than postmenopausal women (32.7% vs 29.5% p=<0.001) (Braun et al. 2005), 250 
indicating that premenopausal bone offers more favourable conditions for DTCs.  A further 251 
study evaluating the incidence of clinically overt bone metastases in over 7,064 women showed 252 
the incidence to be significantly higher in younger women (Harries et al. 2014) suggesting that 253 
premenopausal bone can support the growth of DTCs into bone metastases. Further data on 254 
recurrence patterns of 6,792 breast cancer patients entered into trials conducted by the 255 
International Breast Cancer Study Group showed that younger patients (<35 years) had 256 
significantly higher incidences of bone metastases occurring during the course of their disease 257 
(Colleoni, et al. 2000).  These data suggest that younger women may be at increased risk for 258 
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bone metastases but how and which endocrine hormone is affecting the bone 259 
microenvironment and DTCs is yet to be defined.  260 
 261 
Endocrine influence on bone targeted therapies 262 
Both preclinical and clinical studies have found that the anti-tumour efficacy of osteoclast-263 
targeted agents is influenced by levels of endocrine hormones, with differential effects 264 
according to menopausal status.  These bone-targeted therapies have included bisphosphonates, 265 
the RANKL inhibitor denosumab and the soluble decoy receptor OPG-Fc. 266 
In vivo studies have shown that tumour growth in bone of 12-week old BALBc/nude mice 267 
injected IC with the breast cancer cell line MDA-MB-231 was significantly decreased with 268 
zoledronic acid (Zol) in animals who had undergone OVX (modeling postmenopausal) but not 269 
sham-OVX (modeling premenopausal) (33% vs 86%).  This effect on tumour cells was 270 
independent of the effect of Zol on bone volume with drug-induced increases in both groups 271 
and no significant difference in bone volume between Zol treated groups (Ottewell et al. 2014).  272 
This indicates that the effect of Zol on formation of bone metastases is independent of bone 273 
volume but dependent upon other factors in the bone microenvironment that are differentially 274 
affected by Zol according to the prevailing level of endocrine hormones. Further in vivo data has 275 
supported an Oc mediated differential effect on breast cancer bone metastases according to 276 
menopausal status using the potent inhibitor of osteoclastogenesis, OPG-Fc, which prevents Oc 277 
activation by preventing RANKL-RANK binding similar in mechanism to denosumab (Ottewell, et 278 
al. 2015).  OPG-Fc increased bone volume in 12-week old BALBc/nude mice post OVX and 279 
reduced number and activity of both Oc and Ob.  Tumor growth in bones after IC injection of 280 
MDA-MB-231 cells was decreased by OPG-Fc in OVX animals (7% vs 78.5%) but no effect was 281 
seen in sham-OVX animals.  These data suggest that pharmacological inhibition of Oc’s 282 
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decreases breast tumour growth in bones but only in a bone microenvironment that mimics 283 
postmenopausal (OVX) with low levels of oestradiol and inhibin and high levels of FSH. 284 
 285 
Clinical studies of adjuvant bisphosphonates for early breast cancer have included thousands of 286 
patients treated with both oral and intravenous bisphosphonates.  The largest of the zoledronic 287 
acid studies included AZURE (n=3340)(Coleman, et al. 2011), ABCSG-12 (n=1803)(Gnant, et al. 288 
2011) and ZO-FAST (n=1065)(Coleman, et al. 2013).  AZURE recruited patients with a mixed 289 
menopausal status; premenopausal (45%), unknown menopausal status (9.7%), <5 years since 290 
menopause (14.7) and >5 years since menopause (31%).  Patients were randomised to receive 291 
standard adjuvant therapy +/- zoledronic acid for 5 years and the primary endpoint was disease 292 
free survival (DFS). Patients who were >5 years postmenopausal showed a significantly 293 
improved DFS with the addition of zoledronic acid (ZOL) to standard therapy (ST) (DFS; ST 71%, 294 
ST+ZOL78.2%, HR 0.75, 95%CI 0.59-0.96 p=0.02), but this effect was not seen in any other 295 
patient groups.  ABCSG-12 recruited premenopausal women that all received the goserelin, 296 
which induced a chemical menopause, prior to being randomised to receive 297 
tamoxifen/anastrazole +/- zoledronic acid every 6 months for 3 years.  The primary endpoints 298 
were DFS and zoledronic acid significantly improved DFS compared to endocrine therapy alone 299 
(92% vs 88% p=0.008). A pre-planned subgroup analysis according to age demonstrated a 300 
significant beneficial effect of zoledronic acid on DFS in women >40 years (HR 0.58, 95% CI 0.4-301 
0.83), and these effects were not seen in women <40 years (HR 0.94, 95%CI 0.57-1.56) which 302 
may be due to incomplete ovarian suppression by goserelin in very young women.  ZO-FAST 303 
evaluated addition of zoledronic acid to the aromatase inhibitor letrozole for 5 years in 304 
postmenopausal women with zoledronic acid initiated either at the start of the letrozole (early) 305 
or delayed until evidence of bone mineral density (BMD) loss or fracture.  The primary endpoint 306 
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of this study was change in BMD at 12 months but pre-planned secondary analyses included DFS 307 
and OS.  Patients who started zoledronic acid with letrozole had a 34% decrease in DFS events 308 
(HR 0.66 95%CI 0.44-0.97 p=0.0375) and exploratory analyses according to menopausal status at 309 
randomisation showed that women >5 years postmenopausal or >60 years has a substantially 310 
improved OS with early vs delayed zoledronic acid (HR 0.5; p=0.0224).  This effect was not seen 311 
in women who were recently postmenopausal due to chemotherapy induced ovarian toxicity, 312 
oophorectomy or ovarian suppression.  These trials indicated that adjuvant zoledronic acid was 313 
able to improve disease outcomes only when started in women who had a very suppressed 314 
hypothalamic-pituitary-gonadal (HPG) axis either naturally or chemically.  Similar results were 315 
reported with the adjuvant clodronate trials (Paterson, et al. 2012; Powles, et al. 2006) and a 316 
large meta-analysis of all adjuvant bisphosphonate trials involving >18,000 breast cancer 317 
patients has recently reported and showed that women who were postmenopausal at initiation 318 
of bisphosphonates had fewer recurrences in bone (RR 0.72, 0.60–0.86; 2p=0.0002), at other 319 
distant sites (RR 0.82, 0.74–0.92; 2p=0.0003) and an improved breast cancer mortality (RR 0.82, 320 
0.73–0.93; 2p=0.002) (Coleman et al. 2015). Inhibiting Oc’s by inhibiting the RANKL-RANK 321 
interaction is currently being evaluated in phase III trials of the RANK ligand inhibitor 322 
denosumab and recent data from the ABCSG-18 trial has shown that adjuvant denosumab 323 
reduces the risk of disease recurrence in postmenopausal patients with early stage hormone 324 
receptor positive breast cancer (Gnant M 2015), suggesting that osteoclast inhibition with an 325 
alternative pharmacological agent to bisphosphonates also improves outcomes in patients with 326 
a quiescent HPG axis.  Further data is awaited from the D care study, which is a phase III trial 327 
evaluating addition of denosumab to standard adjuvant therapy for 5 years in pre- and 328 
postmenopausal women to define the population of patients who will derive most benefit.  329 
 330 
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Summary 331 
It is evident that endocrine hormones play a key role in modifying multiple cells within the bone 332 
microenvironment, including bone cells, immune cells, stromal cells and the vasculature, as well 333 
as systemic factors and extracellular matrix components (Holen I 2016a).  This plethora of 334 
cellular effects will undoubtedly have an influence on the homing to and survival of DTCs within 335 
the bone microenvironment, with evidence to suggest this process is enhanced in a 336 
premenopausal bone microenvironment with high oestradiol and inhibin and low FSH.  The 337 
clinical utility of Oc inhibitors, used in early breast cancer, with the aim to prevent bone 338 
metastases and improve disease outcomes (DFS and OS) has been confirmed in a meta-analysis 339 
of large phase III clinical trials involving thousands of women (Coleman et al. 2015).  These trials 340 
have shown that inhibition of the Oc is only effective in preventing metastases when there is a 341 
suppressed HPG axis, either due to natural menopause or chemically induced with GnRH 342 
analogues.  The challenge now is to understand the molecular mechanisms behind this 343 
phenomenon and to evaluate if alternative bone targeted therapies, which act on other cellular 344 
components of the bone microenvironment, may be effective in premenopausal women where 345 
there is a clear need for bone targeted adjuvant therapy. 346 
Page 16 of 26
 17
Declarations of Interest 
The authors declare no conflict of interest that could be perceived as prejudicing the impartiality 
of the research discussed in this review 
 
Funding 
This research did not receive any specific grant from any funding agency in the public, 
commercial or not-for-profit sector. 
 
Acknowledgements  
None 
 
 
 
  
Page 17 of 26
 18
 
References 
Abe M, Shintani Y, Eto Y, Harada K, Kosaka M & Matsumoto T 2002 Potent induction of activin A 
secretion from monocytes and bone marrow stromal fibroblasts by cognate interaction with 
activated T cells. Journal of leukocyte biology 72 347-352. 
 
Aleman-Muench GR & Soldevila G 2012 When versatility matters: activins/inhibins as key 
regulators of immunity. Immunology and cell biology 90 137-148. 
 
Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber B, 
Gebauer G, et al. 2005 A pooled analysis of bone marrow micrometastasis in breast cancer. The 
New England journal of medicine 353 793-802. 
 
Brown HK, Ottewell PD, Evans CA & Holen I 2012 Location matters: osteoblast and osteoclast 
distribution is modified by the presence and proximity to breast cancer cells in vivo. Clinical & 
experimental metastasis 29 927-938. 
 
Burger HG, Dudley EC, Hopper JL, Groome N, Guthrie JR, Green A & Dennerstein L 1999 
Prospectively measured levels of serum follicle-stimulating hormone, estradiol, and the dimeric 
inhibins during the menopausal transition in a population-based cohort of women. The Journal 
of clinical endocrinology and metabolism 84 4025-4030. 
 
Burger HG, Dudley EC, Robertson DM & Dennerstein L 2002 Hormonal changes in the 
menopause transition. Recent progress in hormone research 57 257-275. 
 
Burger HG, Hale GE, Robertson DM & Dennerstein L 2007 A review of hormonal changes during 
the menopausal transition: focus on findings from the Melbourne Women's Midlife Health 
Project. Human reproduction update 13 559-565. 
 
Cameron MD, Schmidt EE, Kerkvliet N, Nadkarni KV, Morris VL, Groom AC, Chambers AF & 
MacDonald IC 2000 Temporal progression of metastasis in lung: cell survival, dormancy, and 
location dependence of metastatic inefficiency. Cancer research 60 2541-2546. 
 
Cannon JG, Cortez-Cooper M, Meaders E, Stallings J, Haddow S, Kraj B, Sloan G & Mulloy A 2010 
Follicle-stimulating hormone, interleukin-1, and bone density in adult women. American journal 
of physiology. Regulatory, integrative and comparative physiology 298 R790-798. 
 
Chiovaro F, Martina E, Bottos A, Scherberich A, Hynes NE, Chiquet-Ehrisman R. 2015. 
Transcriptional regulation of tenascin-W by TGF-beta signaling in the bone metastatic niche of 
breast cancer cells. International journal of cancer. 137(8):1842-54. 
 
 
Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P, von Minckwitz G, 
Sleeboom HP, Forbes J, Barrios C, et al. 2013 Zoledronic acid (zoledronate) for postmenopausal 
women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month 
Page 18 of 26
 19
results. Annals of oncology : official journal of the European Society for Medical Oncology / 
ESMO 24 398-405. 
 
Coleman R, Powles T, Paterson A, Gnant M, Anderson S, Diel I, Gralow J, von Minckwitz G, 
Moebus V, Bergh J, et al. 2015 Adjuvant bisphosphonate treatment in early breast cancer: meta-
analyses of individual patient data from randomised trials. Lancet 386 1353-1361. 
 
Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, Gil M, Houston SJ, 
Grieve RJ, Barrett-Lee PJ, et al. 2011 Breast-cancer adjuvant therapy with zoledronic acid. The 
New England journal of medicine 365 1396-1405. 
 
Colleoni M, O'Neill A, Goldhirsch A, Gelber RD, Bonetti M, Thurlimann B, Price KN, Castiglione-
Gertsch M, Coates AS, Lindtner J, et al. 2000 Identifying breast cancer patients at high risk for 
bone metastases. Journal of clinical oncology : official journal of the American Society of Clinical 
Oncology 18 3925-3935. 
 
Cox TR, Rumney RM, Schoof EM, Perryman L, Hoye AM, Agrawal A, Bird D, Latif NA, Forrest H, 
Evans HR, et al. 2015 The hypoxic cancer secretome induces pre-metastatic bone lesions 
through lysyl oxidase. Nature 522 106-110. 
 
Cross SS, Yang Z, Brown NJ, Balasubramanian SP, Evans CA, Woodward JK, Neville-Webbe HL, 
Lippitt JM, Reed MW, Coleman RE, et al. 2006 Osteoprotegerin (OPG)--a potential new role in 
the regulation of endothelial cell phenotype and tumour angiogenesis? International journal of 
cancer 118 1901-1908. 
 
Drake MT, McCready LK, Hoey KA, Atkinson EJ & Khosla S 2010 Effects of suppression of follicle-
stimulating hormone secretion on bone resorption markers in postmenopausal women. The 
Journal of clinical endocrinology and metabolism 95 5063-5068. 
 
El-Haibi CP, Bell GW, Zhang J, Collmann AY, Wood D, Scherber CM, Csizmadia E, Mariani O, Zhu C, 
Campagne A, et al. 2012 Critical role for lysyl oxidase in mesenchymal stem cell-driven breast 
cancer malignancy. Proceedings of the National Academy of Sciences of the United States of 
America 109 17460-17465. 
 
Ghajar CM, Peinado H, Mori H, Matei IR, Evason KJ, Brazier H, Almeida D, Koller A, Hajjar KA, 
Stainier DY, et al. 2013 The perivascular niche regulates breast tumour dormancy. Nature cell 
biology 15 807-817. 
 
Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, Jakesz R, Seifert M, 
Hubalek M, Pristauz G, et al. 2011 Adjuvant endocrine therapy plus zoledronic acid in 
premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 
randomised trial. The lancet oncology 12 631-641. 
 
Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, Wette V, Balic M, Haslbauer F, 
Melbinger E, Bjelic-Radisic V, Artner-Matuschek S, Fitzal F, Marth C, Sevelda P, Mlineritsch B, 
Steger GG, Manfreda D, Exner R, Egle D, Bergh J, Kainberger F, Talbot S, Warner D, Fesl C, Singer 
CF; Austrian Breast and Colorectal Cancer Study Group. 2015 Adjuvant denosumab in breast 
cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. 
Page 19 of 26
 20
 
Lancet. 1;386(9992):433-43. 
 
Harries M, Taylor A, Holmberg L, Agbaje O, Garmo H, Kabilan S & Purushotham A 2014 Incidence 
of bone metastases and survival after a diagnosis of bone metastases in breast cancer patients. 
Cancer epidemiology 38 427-434. 
 
Holen I 2016a The role of the Microenvironment in Bone Metastasis. Journal of Bone Oncology. 
 
 Holen I, Walker M, Nutter F, Fowles A, Evans CA, Eaton CL, Ottewell PD 2016b Oestrogen 
receptor positive breast cancer metastasis to bone: inhibition by targeting the bone 
microenvironment in vivo. Clin Exp Metastasis 33 211-24 
 
Holen I, Cross SS, Neville-Webbe HL, Cross NA, Balasubramanian SP, Croucher PI, Evans CA, 
Lippitt JM, Coleman RE & Eaton CL 2005 Osteoprotegerin (OPG) expression by breast cancer 
cells in vitro and breast tumours in vivo--a role in tumour cell survival? Breast cancer research 
and treatment 92 207-215. 
 
Hughes R, Qian BZ, Rowan C, Muthana M, Keklikoglou I, Olson OC, Tazzyman S, Danson S, 
Addison C, Clemons M, et al. 2015 Perivascular M2 Macrophages Stimulate Tumor Relapse after 
Chemotherapy. Cancer research 75 3479-3491. 
 
Jeruss JS, Santiago JY & Woodruff TK 2003 Localization of activin and inhibin subunits, receptors 
and SMADs in the mouse mammary gland. Molecular and cellular endocrinology 203 185-196. 
 
Kang Y & Pantel K 2013 Tumor cell dissemination: emerging biological insights from animal 
models and cancer patients. Cancer cell 23 573-581. 
 
Kinder M, Chislock E, Bussard KM, Shuman L & Mastro AM 2008 Metastatic breast cancer 
induces an osteoblast inflammatory response. Experimental cell research 314 173-183. 
 
Klein NA, Houmard BS, Hansen KR, Woodruff TK, Sluss PM, Bremner WJ & Soules MR 2004 Age-
related analysis of inhibin A, inhibin B, and activin a relative to the intercycle monotropic follicle-
stimulating hormone rise in normal ovulatory women. The Journal of clinical endocrinology and 
metabolism 89 2977-2981. 
 
Krassas GE & Papadopoulou P 2001 Oestrogen action on bone cells. J Musculoskelet Neuronal 
Interact 2 143-151. 
 
Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP & Teitelbaum SL 2000 TNF-alpha induces 
osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK 
ligand. The Journal of clinical investigation 106 1481-1488. 
 
Lim PK, Bliss SA, Patel SA, Taborga M, Dave MA, Gregory LA, Greco SJ, Bryan M, Patel PS & 
Rameshwar P 2011 Gap junction-mediated import of microRNA from bone marrow stromal cells 
can elicit cell cycle quiescence in breast cancer cells. Cancer research 71 1550-1560. 
 
Page 20 of 26
 21
Massague J & Obenauf AC 2016 Metastatic colonization by circulating tumour cells. Nature 529 
298-306. 
 
Mastro AM, Gay CV & Welch DR 2003 The skeleton as a unique environment for breast cancer 
cells. Clinical & experimental metastasis 20 275-284. 
 
Miyamot K, Yoshida S, KawauumiI M, Hashimoto K, Kimura T, Sato Y, Kobayashi T, MiauchyI Y, 
Hoshi H, Iwaski R, et al 2011. Osteoclasts are dispensable for hematopoietic stem cell 
maintenance and mobilization. J Exp Med;208(11):2175-81. 
 
 
Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, 
Wagner SN, et al. 2001 Involvement of chemokine receptors in breast cancer metastasis. Nature 
410 50-56. 
 
Nguyen DX, Bos PD & Massague J 2009 Metastasis: from dissemination to organ-specific 
colonization. Nature reviews. Cancer 9 274-284. 
 
Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson 
AL & Weinberg RA 2005 Stromal fibroblasts present in invasive human breast carcinomas 
promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121 
335-348. 
 
Ottewell PD, Wang N, Brown HK, Fowles CA, Croucher PI, Eaton CL & Holen I 2015 OPG-Fc 
inhibits ovariectomy-induced growth of disseminated breast cancer cells in bone. International 
journal of cancer 137 968-977. 
 
Ottewell PD, Wang N, Brown HK, Reeves KJ, Fowles CA, Croucher PI, Eaton CL & Holen I 2014 
Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone 
microenvironment in vivo. Clinical cancer research : an official journal of the American 
Association for Cancer Research 20 2922-2932. 
 
Papayannopoulou T, Priestley GV, Nakamoto B, Zafiropoulos V & Scott LM 2001 Molecular 
pathways in bone marrow homing: dominant role of alpha(4)beta(1) over beta(2)-integrins and 
selectins. Blood 98 2403-2411. 
 
Park SI, Lee C, Sadler WD, Koh AJ, Jones J, Seo JW, Soki FN, Cho SW, Daignault SD & McCauley LK 
2013 Parathyroid hormone-related protein drives a CD11b+Gr1+ cell-mediated positive 
feedback loop to support prostate cancer growth. Cancer research 73 6574-6583. 
 
Paterson AH, Anderson SJ, Lembersky BC, Fehrenbacher L, Falkson CI, King KM, Weir LM, Brufsky 
AM, Dakhil S, Lad T, et al. 2012 Oral clodronate for adjuvant treatment of operable breast 
cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, 
placebo-controlled, randomised trial. The lancet oncology 13 734-742. 
 
Pelekanou V, Kampa M, Kiagiadaki F, Deli A, Theodoropoulos P, Agrogiannis G, Patsouris E, 
Tsapis A, Castanas E & Notas G 2016 Estrogen anti-inflammatory activity on human monocytes is 
Page 21 of 26
 22
mediated through cross-talk between estrogen receptor ERalpha36 and GPR30/GPER1. J Leukoc 
Biol 99 333-347. 
 
Pequeux C, Raymond-Letron I, Blacher S, Boudou F, Adlanmerini M, Fouque MJ, Rochaix P, Noel 
A, Foidart JM, Krust A, et al. 2012 Stromal estrogen receptor-alpha promotes tumor growth by 
normalizing an increased angiogenesis. Cancer research 72 3010-3019. 
 
Perrien DS, Achenbach SJ, Bledsoe SE, Walser B, Suva LJ, Khosla S & Gaddy D 2006 Bone 
turnover across the menopause transition: correlations with inhibins and follicle-stimulating 
hormone. The Journal of clinical endocrinology and metabolism 91 1848-1854. 
 
Png KJ, Halberg N, Yoshida M & Tavazoie SF 2012 A microRNA regulon that mediates endothelial 
recruitment and metastasis by cancer cells. Nature 481 190-194. 
 
Powles T, Paterson A, McCloskey E, Schein P, Scheffler B, Tidy A, Ashley S, Smith I, Ottestad L & 
Kanis J 2006 Reduction in bone relapse and improved survival with oral clodronate for adjuvant 
treatment of operable breast cancer [ISRCTN83688026]. Breast cancer research : BCR 8 R13. 
 
Qiu X, Yuan XG, Jin XL, He X, Zhu L & Zhao XY 2012 Oestrogen-deficiency inducing 
haematopoiesis dysfunction via reduction in haematopoietic stem cells and haematopoietic 
growth factors in rats. Int J Exp Pathol 93 179-187. 
 
Roodman GD 2001 Biology of osteoclast activation in cancer. Journal of clinical oncology : official 
journal of the American Society of Clinical Oncology 19 3562-3571. 
 
Seriwatanachai D, Thongchote K, Charoenphandhu N, Pandaranandaka J, Tudpor K, 
Teerapornpuntakit J, Suthiphongchai T, Krishnamra N. 2008. Prolactin directly enhances bone 
turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB 
ligand/osteoprotegerin ratio. Bone. 42(3):535-46 
 
Shaikh A, Bhartiya D, Kapoor S & Nimkar H 2016 Delineating the effects of 5-fluorouracil and 
follicle-stimulating hormone on mouse bone marrow stem/progenitor cells. Stem cell research & 
therapy 7 59. 
 
Shiozawa Y, Pedersen EA, Havens AM, Jung Y, Mishra A, Joseph J, Kim JK, Patel LR, Ying C, Ziegler 
AM, et al. 2011 Human prostate cancer metastases target the hematopoietic stem cell niche to 
establish footholds in mouse bone marrow. The Journal of clinical investigation 121 1298-1312. 
 
Siraj A, Desestret V, Antoine M, Fromont G, Huerre M, Sanson M, Camparo P, Pichon C, Planeix F, 
Gonin J, et al. 2013 Expression of follicle-stimulating hormone receptor by the vascular 
endothelium in tumor metastases. BMC cancer 13 246. 
 
Smid M, Wang Y, Klijn JG, Sieuwerts AM, Zhang Y, Atkins D, Martens JW & Foekens JA 2006 
Genes associated with breast cancer metastatic to bone. Journal of clinical oncology : official 
journal of the American Society of Clinical Oncology 24 2261-2267. 
 
Page 22 of 26
 23
Sutherland A, Forsyth A, Cong Y, Grant L, Juan TH, Leejk, Klimowicz A, Petrillo SK, Hu J, Chan A, et 
al. 2015.The Role of Prolactin in Bone Metastasis and Breast Cancer Cell-Mediated Osteoclast 
Differentiation. J Natl Cancer Inst. ;108(3). 
 
Tanner MJ, Hadlow NC, Wardrop R. 2011. Variation of female prolactin levels with menopausal 
status and phase of menstrual cycle. Aust N Z J Obstet Gynaecol. 51(4):321-4.  
 
Vivacqua A, De Marco P, Santolla MF, Cirillo F, Pellegrino M, Panno ML, Abonante S & Maggiolini 
M 2015 Estrogenic gper signaling regulates mir144 expression in cancer cells and cancer-
associated fibroblasts (cafs). Oncotarget 6 16573-16587. 
 
Wang H, YuU C, Gao X, Welte T, MuscarellaAM, Tian L, Zhao H, Zhao Z, Dus, Tao J, et al. 2015. 
The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer 
cells. Cancer Cell. 9;27(2):193-210 
 
Wang Z, Xiong S, Mao Y, ChenM, Ma X, Zhou X, Ma Z, Liu F, Huang Z, Luo Q, et al 2016. Periostin 
promotes immunosuppressive premetastatic niche formation to facilitate breast tumour 
metastasis. J Pathol. 239(4):484-95. 
 
Westbrook JA, Cairns DA, Peng J, Speirs V, Hanby AM, Holen I, Wood SL, Ottewell PD, Marshall H, 
Banks RE, et al. 2016 CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis 
Development and Treatment. Journal of the National Cancer Institute 108. 
 
Wilson C, Holen I & Coleman RE 2012 Seed, soil and secreted hormones: potential interactions 
of breast cancer cells with their endocrine/paracrine microenvironment and implications for 
treatment with bisphosphonates. Cancer treatment reviews 38 877-889. 
 
Wilson C, Coleman RE, Nutter F, Brown HK, Holen I (2016). Effects of the female hormone 
inhibin–A in vivo; potential contribution to the antitumour effects of zoledronic acid. Bone: 
DOI 10.1530 abst 5 P105  
 
 
Yan X & Ye TW 2015 Early molecular responses of bone to estrogen deficiency induced by 
ovariectomy in rats. Int J Clin Exp Med 8 5470-5477. 
 
Zhu LL, Blair H, Cao J, Yuen T, Latif R, Guo L, Tourkova IL, Li J, Davies TF, Sun L, et al. 2012 
Blocking antibody to the beta-subunit of FSH prevents bone loss by inhibiting bone resorption 
and stimulating bone synthesis. Proceedings of the National Academy of Sciences of the United 
States of America 109 14574-14579. 
  
 
Page 23 of 26
Figure legends. 
Figure 1. Tumour cell interactions with the bone microenvironment and the effect of 
endocrine hormones. 
Tumour cells home to vascular areas within bone where they interact with bone cells and can 
enter a state of dormancy/quiescence for many years prior to growth.  They are in close contact 
with bone and are thought to occupy the HSC niches.  Following unknown triggers, the tumour 
cells re-gain the ability to proliferate and ultimately form bone metastases or spread to other 
metastatic sites. The table provides a brief overview of the influence of endocrine hormones on 
bone cells involved in the metastatic niche. 
 
Figure 2. Breast tumor cells visualized in close proximity to osteoblasts and blood vessels in 
mouse bone 
Genetically engineered mice with GFP-expressing osteoblasts injected via the intracardiac route 
with CMDii-labelled human MDA-MB-231 cells before sample collection and processing for 
paraffin sections.  Histological sections of tibias were stained with markers for endothelial cells 
using antibodies and DNA was visualized using DAPI. Tumor cells, osteoblasts and blood vessels 
were seen in close proximity to each other within the bone marrow compartment.  
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DTC- Disseminated tumour cell 
CTC- Circulating tumour cell 
HSC- Hemaotopoietic stem cell 
Oc- Osteoclast 
Ob- Osteoblast 
+   activates/increases number 
- inhibits/decreases number  
ER ʹ Oestrogen receptor 
Tumour cell in the 
circulation 
Stay 
dormant? 
 
Die? 
 
CTC 
Develop into 
quiescent 
micromets? 
 
Osteoclast 
Proliferate and  
cause bone 
disease? 
HSC DTC 
Home to bone 
niche(s) 
Osteoblasts 
Return to the 
circulation (and seed 
to other organs)?  
CTC 
Hormone Change in serum levels 
with menopause 
Effect on bone cells Effect on tumour cells in bone 
Oestradiol Decrease -     Oc 
+    Ob 
Promotes spread and growth of ER-positive breast 
cancer cells to bone but not ER-negative (Holen 2016b) 
Inhibins Decrease -     Oc 
+    Ob 
Inhibin A does not affect spread of ER-negative cells to 
bone (Wilson 2016). Effects on growth in bone not 
defined. 
Follicle stimulating 
hormone 
Increase                       -     Oc   (+ Oc in vivo) 
-    Ob 
Effects on spread and growth of cancer cells in bone 
not defined. 
Prolactin Decrease -     Oc 
+    Ob 
Prolactin induces breast cancer cell secretion of 
osteolytic factors (Sutherland 2015). Effects on spread 
and growth of cancer cells in bone not defined. 
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